Program
BTK Inhibitor TT-01488
Also written as “TT-01488 Tablets” and “TT-01488”.
Its studies are mostly in Lymphoma, Mantle-Cell, led by TransThera Sciences (Nanjing).
Furthest: phase 2, since Sep 21, 20263 company-led studies, 2 open or runningNext primary completion: Oct 10, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TransThera Sciences (Nanjing) | 32 open or running | phase 2since Sep 21, 2026 | Feb 21, 2022 | Oct 10, 2029phase 2 · NCT07855016 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 21, 2022First study: phase 1 study in B-Cell MalignanciesFirst studyNCT05275504 · 37 enrolled · United States
- Jan 4, 2023Phase 1 study in B-Cell MalignanciesNCT05683717 · 37 planned · China
- Sep 21, 2026Phase 2 study in Lymphoma, Mantle-CellPhase 2 reachedNCT07855016 · 188 planned · China
Ahead
- Oct 10, 2029Primary completion: phase 2 study in Lymphoma, Mantle-CellNCT07855016
TargetBeta
BTK →read by rule
“An orally bioavailable reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07855016Lymphoma, Mantle-Cell · China | 2 | Not yet recruiting | Oct 10, 2029 | 188 |
| NCT05683717B-Cell Malignancies · China | 1 | Recruiting | Oct 31, 2026 | 37 |
| NCT05275504B-Cell Malignancies · United States | 1 | UNKNOWN | Sep 2022 | 37 |
How it is read
Names in the registry
- “TT-01488 Tablets”, 2 entries
- “TT-01488”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.